ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
ADMA Biologics (Nasdaq: ADMA) has scheduled its fourth quarter and full year 2024 financial results announcement for March 3, 2025, after U.S. financial markets close. The company's management team will host a conference call and audio webcast at 4:30 p.m. ET on the same day to discuss financial results and provide company updates.
Interested participants can access the conference call by dialing (888) 596-4144 with conference ID 5201334. It's recommended to join approximately 10 minutes before the event starts. Those not planning to ask questions are encouraged to listen to the live webcast available on the company's website. An archived replay will be available in the investor section under "Events & Webcasts" at ir.admabiologics.com/events-webcasts.
ADMA Biologics is an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics.
ADMA Biologics (Nasdaq: ADMA) ha programmato l'annuncio dei suoi risultati finanziari del quarto trimestre e dell'anno intero 2024 per il 3 marzo 2025, dopo la chiusura dei mercati finanziari statunitensi. Il team di gestione dell'azienda terrà una conferenza telefonica e una trasmissione audio in diretta alle 4:30 p.m. ET lo stesso giorno per discutere i risultati finanziari e fornire aggiornamenti sull'azienda.
I partecipanti interessati possono accedere alla conferenza telefonica componendo il numero (888) 596-4144 con l'ID conferenza 5201334. Si consiglia di unirsi circa 10 minuti prima dell'inizio dell'evento. Coloro che non intendono porre domande sono invitati ad ascoltare la trasmissione in diretta disponibile sul sito web dell'azienda. Una registrazione archiviata sarà disponibile nella sezione investitori sotto
ADMA Biologics (Nasdaq: ADMA) ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 3 de marzo de 2025, después del cierre de los mercados financieros de EE. UU. El equipo de gestión de la empresa llevará a cabo una conferencia telefónica y una transmisión de audio a las 4:30 p.m. ET el mismo día para discutir los resultados financieros y proporcionar actualizaciones sobre la empresa.
Los participantes interesados pueden acceder a la conferencia telefónica marcando el número (888) 596-4144 con el ID de conferencia 5201334. Se recomienda unirse aproximadamente 10 minutos antes de que comience el evento. Aquellos que no planean hacer preguntas son alentados a escuchar la transmisión en vivo disponible en el sitio web de la empresa. Una repetición archivada estará disponible en la sección de inversores bajo "Eventos y Webcasts" en ir.admabiologics.com/events-webcasts.
ADMA Biologics es una empresa biofarmacéutica comercial de extremo a extremo centrada en la fabricación, comercialización y desarrollo de biológicos especializados.
ADMA Biologics (Nasdaq: ADMA)는 2024년 4분기 및 연간 재무 결과 발표를 2025년 3월 3일, 미국 금융 시장이 마감된 후로 예정하고 있습니다. 회사의 경영팀은 같은 날 오후 4시 30분 ET에 재무 결과를 논의하고 회사 업데이트를 제공하기 위한 전화 회의 및 오디오 웹캐스트를 주최할 것입니다.
참여를 원하는 분들은 (888) 596-4144로 전화하여 회의 ID 5201334를 입력하면 됩니다. 이벤트 시작 약 10분 전에 참여하는 것이 권장됩니다. 질문을 할 계획이 없는 분들은 회사 웹사이트에서 제공되는 라이브 웹캐스트를 듣기를 권장합니다. 아카이브된 재생은 ir.admabiologics.com/events-webcasts의 투자자 섹션에서 "이벤트 및 웹캐스트" 아래에서 확인할 수 있습니다.
ADMA Biologics는 전문 생물학을 제조, 마케팅 및 개발하는 데 중점을 둔 종합 상업 생물 제약 회사입니다.
ADMA Biologics (Nasdaq: ADMA) a prévu l'annonce de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le 3 mars 2025, après la fermeture des marchés financiers américains. L'équipe de direction de l'entreprise animera une conférence téléphonique et un webinaire audio à 16h30 ET le même jour pour discuter des résultats financiers et fournir des mises à jour sur l'entreprise.
Les participants intéressés peuvent accéder à la conférence téléphonique en composant le (888) 596-4144 avec l'ID de conférence 5201334. Il est recommandé de se joindre environ 10 minutes avant le début de l'événement. Ceux qui ne prévoient pas de poser des questions sont encouragés à écouter le webinaire en direct disponible sur le site web de l'entreprise. Un enregistrement archivé sera disponible dans la section investisseurs sous "Événements et Webcasts" à ir.admabiologics.com/events-webcasts.
ADMA Biologics est une entreprise biopharmaceutique commerciale de bout en bout, axée sur la fabrication, la commercialisation et le développement de biologiques spécialisés.
ADMA Biologics (Nasdaq: ADMA) hat die Bekanntgabe seiner Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 für den 3. März 2025 nach dem Schließen der US-Finanzmärkte geplant. Das Management-Team des Unternehmens wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Audio-Webcast abhalten, um die Finanzergebnisse zu besprechen und Unternehmensupdates bereitzustellen.
Interessierte Teilnehmer können die Telefonkonferenz unter (888) 596-4144 mit der Konferenz-ID 5201334 erreichen. Es wird empfohlen, etwa 10 Minuten vor Beginn der Veranstaltung beizutreten. Personen, die keine Fragen stellen möchten, werden ermutigt, den Live-Webcast auf der Unternehmenswebsite anzuhören. Eine archivierte Wiedergabe wird im Investorenbereich unter "Veranstaltungen & Webcasts" auf ir.admabiologics.com/events-webcasts verfügbar sein.
ADMA Biologics ist ein End-to-End-kommerzielles Biopharma-Unternehmen, das sich auf die Herstellung, Vermarktung und Entwicklung von spezialisierten Biologika konzentriert.
- None.
- None.
Conference Call Scheduled for March 3, 2025, at 4:30 p.m. ET
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report fourth quarter and full year 2024 financial results on March 3, 2025, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.
To access the conference call, please dial (888) 596-4144 and refer to conference ID 5201334. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra
INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com
FAQ
When will ADMA Biologics report its Q4 and full year 2024 financial results?
What time is ADMA's Q4 2024 earnings conference call scheduled?
How can investors access ADMA Biologics' Q4 2024 earnings call?
Where can I find the replay of ADMA's Q4 2024 earnings webcast?
What is ADMA Biologics' business focus?
